Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor (NYSE: AVTR) delivers essential materials and technologies powering breakthroughs in life sciences and advanced industries. This news hub provides investors and professionals with direct access to official announcements, including product innovations, financial results, and strategic partnerships shaping the future of bioprocessing and semiconductor manufacturing.
Track critical updates across Avantor's core operations: earnings disclosures detailing performance in pharmaceutical solutions, regulatory filings impacting global supply chains, and advancements in sustainable production methods like their viral vector processing systems. Discover how developments in brands like J.T. Baker and Macron Fine Chemicals influence research and manufacturing efficiency worldwide.
Our curated news collection serves as a decision-making tool for monitoring Avantor's role in enabling scientific progress across 180+ countries. Bookmark this page for real-time insights into leadership changes, facility expansions, and emerging applications in gene therapy support systems.
Avantor, Inc. (NYSE: AVTR) has announced a change in the schedule for its second quarter 2021 earnings release. The financial results will now be disclosed after market close on July 29, 2021, followed by a conference call on July 30, 2021, at 7:30 a.m. EDT. Interested participants can join the call by dialing (866) 211-4132 domestically or (647) 689-6615 internationally. A live webcast will be available on the company’s investor webpage, with a replay accessible until August 28, 2021.
Avantor, Inc. (NYSE: AVTR), a global provider of essential products and services, will release its Q2 2021 financial results after market close on July 28, 2021. The company will host a conference call at 5:00 p.m. EDT to discuss these results. Interested participants can join via phone or through a live webcast on Avantor's investor website. The earnings press release and presentation will also be available. Avantor serves over 225,000 customer locations worldwide, emphasizing its significant role in the life sciences and advanced technologies sectors.
Avantor, Inc. (NYSE: AVTR) has successfully completed the acquisition of Ritter GmbH, enhancing its capabilities in clinical diagnostics and life sciences research. This strategic move integrates Ritter's liquid dispensing technology with Avantor's lab automation solutions, aiming to deliver greater value to biopharma and healthcare customers. Ritter, known for high-quality robotic and liquid handling consumables, specializes in various diagnostic applications, further bolstering Avantor's extensive portfolio. The acquisition received all necessary regulatory approvals.
Avantor (NYSE: AVTR) announced on June 1, 2021, the acquisition of RIM Bio, a prominent Chinese producer of single-use bioprocess bags for biopharmaceutical manufacturing. This strategic purchase enhances Avantor's capacity in the AMEA region, establishing its first single-use production plant there. The acquisition aims to leverage RIM Bio's proprietary technologies, thereby expanding Avantor's offerings in bioproduction and addressing increasing global demand in the biopharma sector. The move aligns with Avantor's ongoing investments in China.
Avantor, a global leader in mission-critical products for life sciences, will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. Michael Stubblefield, President and CEO, will represent the company starting at 9:40 a.m. EDT. A live webcast of the event will be available on Avantor's investor relations website, with a replay accessible until June 30, 2021.
Avantor serves over 225,000 locations across 180 countries, providing essential services across various industries, including biopharma and healthcare.
Avantor, Inc. (NYSE: AVTR) reported strong financial results for Q1 2021, with net sales of $1.79 billion, a 17.5% increase year-over-year. Net income surged 248.9% to $164 million, while adjusted EBITDA rose 38.2% to $363.1 million. The company achieved an adjusted net leverage of 3.5x. Significant growth was seen across all regions, particularly in AMEA, which experienced a 32.0% increase in net sales. The acquisition of Ritter is expected to enhance Avantor's product offerings. The company is on track to exceed $800 million in free cash flow for the year.
Avantor (NYSE: AVTR) will participate in a virtual fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021. Michael Stubblefield, President and CEO, will represent the company, beginning at approximately 9:30 a.m. EDT. The event will be accessible via a live webcast on Avantor's investor relations website and will be available for replay until May 31, 2021. Avantor is a leading provider of critical products and services across multiple industries, serving over 225,000 customers in more than 180 countries.
Avantor Inc. (NYSE: AVTR) announced plans to enhance its global capacity for single-use technologies crucial in biologics and vaccine production. This expansion includes a 30% increase in manufacturing footprint and a doubling of cleanroom space across the U.S. and Europe, responding to rising demand for monoclonal antibodies, gene therapies, and COVID-19 vaccines. Recent expansions include its North Carolina facility and a new cleanroom in Devens, Massachusetts, expected by mid-year. A second European facility will also open in the Netherlands, ensuring efficient supply to biopharma clients.
Avantor has declared a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, representing a yield of 1.560%. The dividend will be paid on May 17, 2021, to shareholders on record as of April 1, 2021. This move underscores Avantor's commitment to returning value to shareholders and reflects confidence in its business model amidst ongoing global challenges.
Avantor (NYSE: AVTR) announced its acquisition of Ritter GmbH for approximately €890 million in an all-cash deal, subject to adjustments and performance milestones. Ritter is a leading manufacturer of robotic and liquid handling consumables with a market potential of nearly $7 billion. This acquisition aims to enhance Avantor's offerings in the biopharma and healthcare sectors, and is expected to be accretive to adjusted EPS immediately upon closing. The deal will be financed through available cash and term loans, with a closing anticipated in Q3 2021.